Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 5.77 USD 11.61% Market Closed
Market Cap: 444.3m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALT stock under the Base Case scenario is 5.16 USD. Compared to the current market price of 5.77 USD, Altimmune Inc is Overvalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALT Relative Value
Base Case
5.16 USD
Overvaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

20 873.8
P/S
P/S
Price to Sales
20 873.8
vs History
4
vs Industry
0
Median 3Y
491.2
Median 5Y
97.9
Industry
6.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-5.4
Industry
22.4
Forward
-3.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.8
Industry
19.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.7
Industry
23.2
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
34
vs Industry
27
Median 3Y
3
Median 5Y
2.7
Industry
2.5
More Details
14 279.2
EV/S
EV/S
Enterprise Value to Sales
14 279.2
vs History
4
vs Industry
0
Median 3Y
238
Median 5Y
55.4
Industry
7.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
32
Median 3Y
-3.2
Median 5Y
-3.4
Industry
4
Forward
-2.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
31
Median 3Y
-3.2
Median 5Y
-3.4
Industry
3.7
Forward
-2.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
32
Median 3Y
-4.4
Median 5Y
-4.4
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
29
Median 3Y
-4.4
Median 5Y
-4.4
Industry
3.4
More Details
39.6
EV/IC
EV/IC
Enterprise Value to IC
39.6
vs History
26
vs Industry
6
Median 3Y
29.4
Median 5Y
10.3
Industry
4.6
More Details

Multiples Across Competitors

ALT Competitors Multiples
Altimmune Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Altimmune Inc
NASDAQ:ALT
417.5m USD 20 873.8 -4.4 -2.8 -2.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 047 871.8 -166 577.3 -202 278 -199 969.8
US
Abbvie Inc
NYSE:ABBV
350.4B USD 6.2 82.7 16.3 24.6
US
Amgen Inc
NASDAQ:AMGN
151B USD 4.5 36.9 15.2 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.8B USD 11.7 -240.4 26.3 27.6
US
Gilead Sciences Inc
NASDAQ:GILD
129.2B USD 4.5 269.1 10.6 13.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 010.1 -512.9 -558.5 -543.6
AU
CSL Ltd
ASX:CSL
125B AUD 5.3 29.2 18 22.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.4B USD 4.7 15 9.5 10.6
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.4 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
35.1B EUR 18.2 47.7 -2 697.2 -1 808.3
P/S Multiple
Revenue Growth P/S to Growth
US
Altimmune Inc
NASDAQ:ALT
Average P/S: 3 188 257.3
20 873.8
1 155%
18.1
FR
Pharnext SCA
OTC:PNEXF
35 047 871.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
E
Epizyme Inc
F:EPE
2 010.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
18.2
39%
0.5
P/E Multiple
Earnings Growth PEG
US
Altimmune Inc
NASDAQ:ALT
Average P/E: 80.1
Negative Multiple: -4.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 577.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
82.7
87%
1
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240.4 N/A N/A
US
Gilead Sciences Inc
NASDAQ:GILD
269.1
187%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.9 N/A N/A
AU
CSL Ltd
ASX:CSL
29.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A
NL
argenx SE
XBRU:ARGX
47.7
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Altimmune Inc
NASDAQ:ALT
Average EV/EBITDA: 16
Negative Multiple: -2.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 278 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
AU
CSL Ltd
ASX:CSL
18
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.5
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 697.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Altimmune Inc
NASDAQ:ALT
Average EV/EBIT: 20.9
Negative Multiple: -2.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 969.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
17%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.6 N/A N/A
AU
CSL Ltd
ASX:CSL
22.6
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.6
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 808.3 N/A N/A

See Also

Summary
ALT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALT stock valuation using valuation multiples.
Wall Street Estimates
ALT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.